Relationship between miR-29a levels in the peripheral blood and sepsis-related encephalopathy

Wei Guo¹, Yanhui Li², Qi Li²

¹Department of Intensive Medicine, The First People’s Hospital of Chenzhou, Chenzhou 423000, Hunan Province, China; ²Department of Electrocardiology, The First People’s Hospital of Chenzhou, Chenzhou 423000, Hunan Province, China

Received January 24, 2021; Accepted February 24, 2021; Epub July 15, 2021; Published July 30, 2021

Abstract: Objective: This study aimed to explore the relationship between peripheral blood miR-29a and sepsis-related encephalopathy (SAE). Methods: A total of 120 patients with sepsis admitted to our hospital from March 2018 to October 2019 were selected as research subjects. They were divided into a SAE group (30 cases) and an unrelated encephalopathy group (90 cases) according to whether the patients were complicated with SAE. The levels of miR-29a in the peripheral blood, neuron-specific enolase (NSE), S100β calcium binding protein (S100β) and interleukin-6 (IL-6) in serum were determined, and the relationship between miR-29a in the peripheral blood and the diagnosis and prognosis prediction in SAE patients was analyzed. Results: Compared with the unrelated encephalopathy group, the levels of miR-29a in peripheral blood, NSE, S100β and IL-6 in serum of patients in the SAE group were elevated notably. miR-29a in the peripheral blood, and NSE, S100β, IL-6 in the serum of patients who died and survived within 28 days were detected, and the levels of these four indexes in the death group were significantly higher than those in the survival group. Correlation analysis revealed that miR-29a in the peripheral blood was positively correlated with the levels of NSE, S100β and IL-6 in serum. According to Receiver Operating Characteristic (ROC) curve analysis, miR-29a in the peripheral blood can be used as a potential biomarker to predict whether sepsis is complicated with SAE and the relative prognosis. Conclusion: miR-29a is closely associated with the development of SAE, and miR-29a in the peripheral blood can be used as a potential biological index to predict whether sepsis is complicated with SAE and indications of a poor prognosis.

Keywords: miR-29a, sepsis, diagnosis, prognosis

Introduction

Sepsis is the leading cause of death in both medical and surgical intensive care units (ICU). In most cases, impaired consciousness of varying severity is an early warning sign of the development of sepsis. Sepsis-associated encephalopathy (SAE) is the most common type of encephalopathy in the ICU and it is defined as a state of diffuse brain dysfunction caused by inflammatory responses to various infections, in which the inflammatory process does not directly affect the symptoms of the central nervous system, and the main symptom is impaired consciousness [1]. Most patients develop SAE symptoms before meeting the criteria of sepsis, which ranges from illness behaviors and acute phase symptoms in delirium coma, and can lead to long-term cognitive impairment [2]. In addition, SAE has been identified as associated with increased mortality, high hospitalization costs, and prolonged length of stay, followed by persistent cognitive deficits and limitations in physical effects [3]. Therefore, early identification and timely intervention of brain injury are crucial for the survival and prognosis of sepsis patients.

miRNA is a small non-coding RNA molecule that is considered to be related to the occurrence and progression of various tumors, which can regulate post-transcriptional levels by binding to the 3'-UTR of target mRNA [4]. miRNA biogenesis is dynamic and has great diversity, and maladjusted miRNA plays a key part in the progression of various diseases [5]. Circulating miRNA can also be used as a potential biomarker for the diagnosis and prognosis of various diseas-
Table 1. Primer sequence

<table>
<thead>
<tr>
<th></th>
<th>Upstream primer (5'-3')</th>
<th>Downstream primer (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-29a</td>
<td>CTGCTGATCATGGGGCTCCT</td>
<td>CTCCACAGGCTCGGGTTG</td>
</tr>
<tr>
<td>U6</td>
<td>CTCGCTTCGCGACACA</td>
<td>AACGCTCCAGAAATTTTCG</td>
</tr>
</tbody>
</table>

Table 2. Comparison of general data between the two groups [n (%)] (X±sd)

<table>
<thead>
<tr>
<th>Classification</th>
<th>SAE group (n=30)</th>
<th>Unrelated encephalopathy group (n=90)</th>
<th>t/χ² value</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td>0.342</td>
<td>0.900</td>
</tr>
<tr>
<td>Male</td>
<td>17 (56.67)</td>
<td>42 (46.67)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>13 (43.33)</td>
<td>48 (53.33)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>57.61±4.16</td>
<td>56.91±4.85</td>
<td>0.708</td>
<td>0.480</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>171.61±6.91</td>
<td>172.14±6.17</td>
<td>0.596</td>
<td>0.551</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>54.62±4.62</td>
<td>55.19±4.18</td>
<td>0.629</td>
<td>0.530</td>
</tr>
<tr>
<td>Hypertension history</td>
<td></td>
<td></td>
<td>0.878</td>
<td>0.348</td>
</tr>
<tr>
<td>Present</td>
<td>4 (13.33)</td>
<td>19 (21.11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>26 (86.67)</td>
<td>71 (78.89)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes history</td>
<td></td>
<td></td>
<td>0.658</td>
<td>0.417</td>
</tr>
<tr>
<td>Present</td>
<td>7 (23.33)</td>
<td>28 (31.11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>23 (76.67)</td>
<td>62 (68.89)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td>0.117</td>
<td>0.732</td>
</tr>
<tr>
<td>Present</td>
<td>20 (66.67)</td>
<td>63 (70.00)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>10 (33.33)</td>
<td>27 (30.00)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drinking</td>
<td></td>
<td></td>
<td>0.378</td>
<td>0.538</td>
</tr>
<tr>
<td>Present</td>
<td>24 (80.00)</td>
<td>67 (74.44)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>6 (20.00)</td>
<td>23 (25.56)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days in ICU</td>
<td>4.51±1.15</td>
<td>3.97±1.46</td>
<td>1.842</td>
<td>0.067</td>
</tr>
<tr>
<td>Death within 28 days</td>
<td>7 (23.33)</td>
<td>10 (11.11)</td>
<td>2.764</td>
<td>0.096</td>
</tr>
</tbody>
</table>

Figure 1. miR-29a expression in the two groups. According to the results, compared with the unrelated encephalopathy group, miR-29a in peripheral blood of patients in the SAE group elevates markedly (P<0.05), Note: * vs. the unrelated encephalopathy group (P<0.05).

Materials and methods

General data

A total of 120 patients with sepsis admitted to The First People’s Hospital of Chenzhou from March 2018 to October 2019 were recruited as research subjects. They were divided into a SAE group (30 cases) and an unrelated encephalopathy group (90 cases) according to whether they were complicated with SAE.

Inclusion and exclusion criteria

Inclusion criteria: Patients met the diagnostic criteria of sepsis or SAE [10, 11]; patients agreed and signed the informed consent. This experiment was approved by the Ethics Committee of our hospital.

Exclusion criteria: Patients who underwent cardiopulmonary cerebral resuscitation; patients who were complicated with cerebrovascular...
Relationship between miR-29a and sepsis associated encephalopathy

Figure 2. NSE, S100β, and IL-6 expression in the two groups. According to the results, NSE, S100β and IL-6 levels are notably higher in the SAE group than in the unrelated encephalopathy group (P<0.05). A. NSE expression in the two groups. B. S100β expression in the two groups. C. IL-6 expression in the two groups. Note: * vs. the unrelated encephalopathy group (P<0.05).

Figure 3. miR-29a expression in the dead and surviving patients within 28 days. Compared with the surviving patients, the index level of the dead patients was considerably higher (P<0.05). Note: * vs. the survival group (P<0.05).

accidents; patients who were complicated with intracranial lesions; and patients who were complicated with other metabolic encephalopathy.

Main instruments

The main instruments used in this study included: centrifuge (Wuhan Khayal Bio-Technology Co., Ltd.), mirVanaTM miRNA Isolation Kit (Shanghai Huzhen Industrial Co., Ltd.), ultraviolet and visible spectrophotometer (Wuhan Chundu Biotechnology Co., Ltd.), TaqMan MicroRNA reverse transcription kit (Beijing Biolab Technology Co., Ltd.), real-time fluorescence quantification PCR system (Shenzhen Enco Science and Technology Co., Ltd.), and miRNA RT-qPCR research kit (Shanghai Genetimes Biotechnology Co., Ltd.). miR-29a and internal reference primer synthesis were provided by Shanghai Beyotime Biotechnology Co., Ltd., as shown in Table 1.

Methods

Five ml of fasting venous blood were taken from both groups of patients early in the morning. The serum was separated by centrifugation (10×g at 4°C for 15 min) after standing for 20 min and stored at -80°C under liquid nitrogen freezing. Serum neuron-specific enolase (NSE), S100 calcium binding protein β (S100β) and Interleukin-6 (IL-6) levels were determined by enzyme-linked immunosorbent assay (ELISA). The total RNA was extracted according to the instructions of mirVanaTM miRNA Isolation Kit. The concentration of RNA was measured by ultraviolet and visible spectrophotometer.
According to TaqMan MicroRNA reverse transcription kit, RNA was reverse transcribed into cDNA, and PCR amplification experiment was conducted with cDNA as template and U6 as internal reference gene. Based on the miRNA RT-qPCR research kit, miR-29a was quantitatively determined by real-time fluorescence quantitative PCR system. PCR amplification cycle conditions were as follows: 95°C for 30 s, 95°C for 5 s, and 60°C for 30 s, with a total of 40 cycles. Three duplicate wells were set in each group, and the experiment was repeated three times. The results were expressed by $2^{-\Delta\Delta CT}$.

**Statistical analysis**

SPSS 24.0 (IBM Corp, Armonk, NY, USA) was applied for statistical analysis, and GraphPad Prism 8 (GraphPad Software, San Diego, USA)
Relationship between miR-29a and sepsis associated encephalopathy

Figure 6. ROC curve of miR-29a in diagnosing SAE patients.

was used for data plotting. The t-test was used to represent the measurement data, expressed as mean ± standard deviation (\( \bar{x} \pm sd \)). The count data were expressed as number of cases/percentage [n (%)], and the chi-square test was applied for comparison between groups. The diagnostic value of serum miR-29a in patients with SAE was analyzed by the Receiver Operating Characteristic (ROC) curve. The correlation was analyzed by Pearson Correlation Coefficient. P<0.05 was considered statistically significant.

Results

General data of patients in the two groups

There was no statistically significant difference in age, gender, living habits and other aspects between the two groups (P>0.05), as shown in Table 2.

miR-29a expression in the two groups

miR-29a in SAE and unrelated encephalopathy groups were (1.46±0.12) and (1.17±0.15), respectively. Compared with the unrelated encephalopathy group, miR-29a in the peripheral blood of patients in the SAE group was significantly elevated (P<0.05), as shown in Figure 1.

NSE, S100β, and IL-6 expression in the two groups

In the SAE group, the expression of NSE, S100β, and IL-6 were (10.16±2.11), (0.27±0.06), and (229.15±29.61), respectively. In the unrelated encephalopathy group, the expression of NSE, S100β, and IL-6 were (8.62±1.62), (0.18±0.04), and (196.71±18.62), respectively. The above results revealed that NSE, S100β and IL-6 levels were significantly higher in the SAE group than in the unrelated encephalopathy group (P<0.05). More details are shown in Figure 2.

miR-29a expression in the dead and surviving patients within 28 days

miR-29a expression in patients who died and survived for 28 days were (1.54±0.19) and (1.28±0.15), respectively. Compared with the surviving patients, miR-29a in dead patients was considerably higher (P<0.05). More details are shown in Figure 3.

NSE, S100β and IL-6 expression in the dead and surviving patients within 28 days

In dead patients, the expression of NSE, S100β and IL-6 were (13.41±2.18), (0.30±0.08), and (238.16±27.62), respectively. In the surviving patients, however, the expression of NSE, S100β and IL-6 were (10.17±1.61), (0.21±0.06), and (216.81±24.16), respectively. Compared with the survival group, these levels in the death group were significantly higher (P<0.05). More details are shown in Figure 4.

Correlation analysis of miR-29a levels with NSE, S100β and IL-6 levels

We applied Pearson Correlation Coefficient for analysis, and found that miR-29a in the peripheral blood was markedly positively associated with the levels of NSE, S100β and IL-6 in serum (r=0.599, 0.659, 0.520; P<0.05). More details are shown in Figure 5.

Value of miR-29a for diagnosing SAE

By plotting the ROC curves, it was found that the area under the curve (AUC) of miR-29a for the diagnosis of SAE was 0.872, as shown in Figure 6 and Table 3.

Prognostic value of miR-29a for indicating a poor prognosis in SAE patients

By plotting the ROC curve, it was found that the AUC of miR-29a predicting poor prognosis was 0.876, as detailed in Figure 7 and Table 4.

Discussion

Approximately 70% of patients with SAE develop severe polyneuropathy and myopathy, mani-
Relationship between miR-29a and sepsis associated encephalopathy

Table 3. ROC parameters of miR-29a in diagnosing SAE patients

<table>
<thead>
<tr>
<th>Index</th>
<th>AUC</th>
<th>95% CI</th>
<th>S.E</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-29a</td>
<td>0.872</td>
<td>0.7796 to 0.9649</td>
<td>0.047</td>
<td>73.33</td>
<td>86.67</td>
</tr>
</tbody>
</table>

Figure 7. ROC curve of miR-29a in predicting poor patient prognosis.

The development of illness behavior may be associated with proinflammatory factors [18]. NSE is an intracellular glycolytic enzyme which is mainly expressed by neurons, and can be detected in serum after neuronal injury [19]. Elevated levels of NSE in the first few days after cardiac arrest may indicate a sustained release of NSE, which may reflect an association between persistent secondary neurological injury and poor prognosis [20]. S100β is a protein of the S-100 protein family. It is glial-specific and mainly expressed by mature astrocytes [21]. Elevated S100β levels can accurately reflect the existence of neuropathological conditions, including craniocerebral trauma and neurodegenerative diseases [22]. IL-6 is a typical cytokine to maintain balance in vivo. When the steady state is disrupted by infection or tissue damage, IL-6 will be produced immediately, which helps the host resist this emergency pressure by activating an acute phase of the immune response [23]. However, the maladjusted excessive or continuously synthesized IL-6 can have pathological effects on the acute systemic inflammatory response syndrome and chronic immune-mediated diseases, respectively [24, 25]. In this study, NSE, S100β and IL-6 increased in SAE, and Pearson correlation coefficient analysis revealed a positive relationship between miR-29a and them, suggesting that NSE, S100β, IL-6 and miR-29a may have synergistic effects on the occurrence and progression of diseases in SAE patients. However, the specific regulatory mechanisms of NSE, S100β, IL-6 and miR-29a in patients with SAE have not been elaborated in clinical practice. Subsequent experiments revealed that the levels of NSE, S100β, IL-6 and miR-29a in patients with SAE were remarkably higher than those in the surviving patients within 28 days. The above data suggested that the continuous increase of miR-29a levels may be related to a poor prognosis of SAE patients. We also analyzed the value of miR-29a in predicting a poor prognosis in SAE patients by ROC curves, and
obtained an AUC of 0.876, suggesting that miR-29a may have a higher efficacy in predicting poor prognosis in SAE patients. Therefore, the detected expression of serum miR-29a may be a reliable biomarker for early diagnosis and prognosis prediction of SAE patients, but the specific regulation mechanism needs further discussion.

The current experiment is still deficient. We did not explore the specific mechanism of the effect between NSE, S100β, IL-6 and miR-29a, nor did we explore the effect of miR-29a on the cellular and biological functions of SAE patients. We will continue to study and improve the results.

In summary, miR-29a is highly expressed in SAE patients, and serum miR-29a may be used as a molecular marker for early diagnosis and prognosis prediction of SAE patients.

Acknowledgements
This study is financially supported by the Chenzhou Science and Technology Project Fund (ZDYF2020107).

Disclosure of conflict of interest
None.

Address correspondence to: Qi Li, Department of Electrocardiology, The First People’s Hospital of Chenzhou, Luojiajing 102, Chenzhou 423000, Hunan Province, China. Tel: +86-18073504388; E-mail: Lqiyi8681103@163.com

References
Relationship between miR-29a and sepsis associated encephalopathy


